TRICARE Experimental Treatment Coverage & Rules (2026) | TRICARE.com

*TRICARE.com is an independent reference site and is not affiliated with the Department of Defense. For official policy, visit TRICARE.mil.*

## Quick answer TRICARE generally does **not** cover experimental or investigational treatments, including drugs, devices, or procedures that have not yet been proven safe and effective through peer-reviewed medical research. However, there are specific exceptions for life-threatening illnesses, rare diseases, and certain federally sanctioned clinical trials.

Details

TRICARE’s coverage policy is governed by federal law (32 CFR 199.4), which mandates that any medical intervention must be "proven" to be effective. A treatment is considered experimental or investigational if it is not yet the "standard of medical practice."

### The "Proven" Standard To move from "experimental" to "covered," a procedure or drug must meet these criteria: * **FDA Approval:** For drugs and devices, they must be fully approved (not just an Emergency Use Authorization) for the specific use intended. * **Peer Review:** Published studies in major medical journals must demonstrate that the treatment improves health outcomes. * **National Consensus:** Major medical organizations must recognize it as a standard treatment.

### Common Exceptions While the "no experimental" rule is strict, TRICARE provides pathways for coverage in specific scenarios:

* **Cancer Clinical Trials:** TRICARE may cover "routine costs" (physician visits, lab tests, and imaging) for patients participating in Phase I, Phase II, or Phase III clinical trials sponsored by the National Cancer Institute (NCI). It does *not* cover the cost of the experimental drug itself if it is provided free by the manufacturer. * **Rare Diseases:** TRICARE may grant a waiver for treatments of rare diseases (defined as affecting fewer than 200,000 people in the U.S.) if there is no other effective standard of care. * **Off-Label Drug Use:** If a provider prescribes an FDA-approved drug for a condition it wasn't originally intended for, TRICARE may cover it if at least two high-quality peer-reviewed studies support that specific use.

### The Appeals Process If a claim for a new treatment is denied as "investigational," you have 90 days to file an appeal. In 2026, these appeals are processed by: * **East Region:** Humana Military * **West Region:** TriWest Healthcare Alliance * **Overseas:** International SOS

Note: TRICARE Prime beneficiaries usually require a referral and authorization from their Primary Care Manager (PCM) and the regional contractor before seeking any treatment that could be flagged as experimental.

## Who this affects * **Active Duty Service Members (ADSMs):** Require specific military medical command approval for any non-standard treatment. * **Active Duty Family Members (ADFMs):** Covered under clinical trial exceptions if criteria are met. * **Retirees and their families:** Subject to standard "proven" requirements; costs vary by plan year (e.g., TRICARE Select 2026 cost-shares apply). * **National Guard and Reserve:** Those on TRICARE Reserve Select (TRS) follow the same clinical trial protocols as active-duty families.

## Sources * **TRICARE.mil:** [Unproven Procedures and Treatments](https://tricare.mil/CoveredServices/IsItCovered/UnprovenProcedures) * **Defense Health Agency (DHA):** [TRICARE Policy Manual 6010.63-M](https://manuals.health.mil/) * **TriWest Healthcare Alliance:** [Provider Clinical Resources (West Region)](https://www.triwest.com) * **Humana Military:** [Medical Coverage Policies (East Region)](https://www.humanamilitary.com)